Health & Medicine · The Record
FDA said its inspection reorganization is "not a move to generalists"; GAO recorded 105 investigators hired and 105 lost
The agency's defense of its October 1 restructuring sits next to two trade descriptions of what the plan actually does, and next to a government audit that located the inspection shortfall in staff turnover rather than org charts.
Two senior FDA officials defended the agency's coming inspection reorganization in an FDA Voices post published in early August 2026, RAPS/Regulatory Focus reported. Elizabeth Miller, FDA associate commissioner for inspections and investigations, and Lowell Zeta, acting chief of staff and deputy commissioner for strategic initiatives, wrote, as quoted by RAPS, that "The next-generation [Office of Inspections and Investigations] OII workforce model is not a move to generalists ...". RAPS also reported a statement that the model "has been carefully designed to deepen talent by expanding investigators' capabilities, strengthening specialized expertise".
What the operative change is described as doing
Food Safety Tech, writing about the reorganization plan it identifies as Simple Reform and dates to October 1, 2026, described the change as folding "food & beverage, medical devices and clinical research inspectorates into a mixed pool of generalists". Food Safety Magazine described the same effect on the field force: "Specialized field inspectors who oversee specific product categories will now operate as generalists, conducting inspections and investigations across multiple industries."
Both outlets also reported that administrative functions move to a shared service model, with the FDA Office of Operations taking on human resources, finance and information technology work that individual centers had handled.
The Federal Register notice that enacts the change was not directly retrievable for this article. The descriptions above are trade-press accounts of it, not the notice text.
The earlier restructuring pointed the other way
The previous restructuring of FDA's field operations moved investigators toward the product centers. A passage in The FDA Group's account of that earlier change states that the alignment would "bring investigators closer to the center program staff", and a further passage says the reassignment of staff to product centers could result in investigators who are more specialized in specific product areas. The snapshot carries no attribution marker on those lines, so it cannot be determined here whether they are the consultancy's own words or quoted agency speech.
That distinction matters for how much weight the contrast can carry. Nothing in the material available for this article shows FDA itself, in its own voice, making the specialization argument for the earlier move. What can be said is that the direction of travel described for the earlier change - investigators pulled closer to product-specific programs - runs opposite to the mixed generalist pool the trade accounts describe for October 1.
What GAO measured
The U.S. Government Accountability Office examined FDA's inspection workforce in GAO-25-106775, using hiring and vacancy data running through June 2024. The report predates the 2026 reorganization and is evidence about the underlying retention problem, not an assessment of this plan.
GAO reported that from the start of fiscal year 2022 to June 2024, ORA hired 105 new investigators into a general pool of roughly 230 authorized positions and lost 105 over the same period. GAO reported 1,065 total inspections in fiscal year 2023, a 40 percent increase over fiscal year 2022, and 36 percent below the 1,671 inspections conducted in fiscal year 2019. The fiscal 2023 total was 621 foreign and 444 domestic inspections.
Two different vacancy counts appear in the report, and they measure different populations. GAO reported total investigator vacancies rising from 25 in November 2021 to 51 as of June 2024. For the narrower group of investigators who inspect foreign and domestic manufacturers, GAO reported 37 vacancies as of June 2024, a 16 percent vacancy rate, up from 9 percent in November 2021. They are not the same series and should not be read as one.
The workforce GAO described was also young in the job: about 63 percent of current investigators had been hired within the previous five years as of May 2024, and 36 percent of investigators in the general pool did not have the experience needed to conduct independent foreign inspections.
On cause, GAO reported the agency's own diagnosis. ORA identified travel, pay, training, workload and work-life balance as the root causes of the morale problems driving attrition, and, in GAO's words, "Officials identified travel as the biggest cause of attrition, including both the amount of travel and the conditions of travel." GAO's product page notes that investigators can travel up to 75 percent of the time. GAO recommended action plans covering the remaining root causes; HHS agreed with the recommendation. As of the report, FDA was implementing action plans on pay and training but had not yet developed plans fully addressing travel, workload and work-life balance.
Analysis
Nothing in the record assembled here measures whether the new workforce model deepens expertise or thins it. No study, dataset or audit of the October 1 structure exists yet, because the structure does not exist yet. That is the honest limit of what can be said.
What can be set side by side is this: the agency's published defense asserts strengthened specialization, while two trade descriptions of the instrument that enacts the change describe product-specific inspectorates being merged into a mixed generalist pool. Those two statements can both be reported, but they cannot both be a full description of the same document. Readers can weigh the claim against the description.
The second gap is what the plan does not touch. The constraint GAO documented was people leaving, with travel named by agency officials as the biggest driver, and with hiring exactly cancelled by losses across the period examined. A plan that reassigns which industries an investigator covers is not, on its face, a plan about travel conditions, pay, workload or work-life balance. Whether covering more product categories across wider territory raises or lowers an individual investigator's travel burden is not measured in any source available here. It is a plausible mechanism, not a finding, and it should not be reported as one.
Prediction, checkable by June 30, 2027: FDA will not have published action plans that fully address travel, workload and work-life balance, the three root causes GAO reported as still unaddressed. The check is the recommendation status published on GAO's page for GAO-25-106775 on that date.
Also in the roundup
RAPS reported that FDA is establishing the Inspectional Affairs Council, a cross-agency governance body that addresses inspectional issues. RAPS also reported statements, without a speaker identified in the passages available here, that the current investigational new drug process is outdated and failing, that the United States is falling behind in attracting researchers to conduct early-phase clinical trials, especially compared to China, and that the steps under consideration include an Expedited IND Pilot program.
OncoDaily, reporting on the same pilot proposal, wrote that Phase 1 trials that may require up to two years to complete in the United States can be completed in approximately nine months in China, and described the stated aim as being to "accelerate development without reducing regulatory standards or compromising patient safety".
Sourcing note
FDA's website did not return the FDA Voices post for this article. The Miller and Zeta wording above is as reported by RAPS/Regulatory Focus and is not independently confirmed against the agency's own page. The Federal Register notice was likewise not directly accessible, so no language is quoted from it here. Daily Pol has received no reply from the named officials or from FDA.